{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:07:49Z","timestamp":1784092069553,"version":"3.55.0"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008092","name":"Jinhua Science and Technology Bureau","doi-asserted-by":"publisher","award":["2025-4-062"],"award-info":[{"award-number":["2025-4-062"]}],"id":[{"id":"10.13039\/501100008092","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Invasive lobular carcinoma (ILC) demonstrates a distinctive propensity for gastrointestinal metastasis that differs from invasive ductal carcinoma (IDC). In mixed breast carcinomas, intratumoral heterogeneity poses challenges for disease surveillance and treatment assessment. Moreover, gastrointestinal adverse effects associated with CDK4\/6 inhibitors, such as abemaciclib, may lead to diagnostic overshadowing, potentially delaying recognition of metastatic disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case description<\/jats:title>\n                    <jats:p>A 68-year-old woman with mixed IDC and ILC underwent mastectomy following neoadjuvant chemotherapy. Histopathological evaluation revealed significant heterogeneity, with a luminal A IDC component and a triple-negative ILC component, the latter involving axillary lymph node metastases. During treatment with letrozole and abemaciclib, the patient developed progressive abdominal pain accompanied by rising carcinoembryonic antigen (CEA) levels, which were initially attributed to treatment-related toxicity. While bone metastases with a luminal phenotype remained radiographically stable, colonoscopy revealed an obstructing lesion in the descending colon. Biopsy confirmed metastatic carcinoma with a triple-negative profile (GATA3-positive, CDX2-negative), consistent with the primary ILC component and distinct from the bone metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case highlights that persistent or evolving gastrointestinal symptoms during CDK4\/6 inhibitor therapy warrant thorough evaluation for metastatic disease, particularly in patients with ILC. It also suggests that aggressive minor components in mixed tumors may have important clinical and prognostic implications. It emphasizes the importance of re-biopsy to identify phenotypic discordance and current therapeutic targets, informing timely and appropriate modifications to the treatment strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1802301","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:44:09Z","timestamp":1784090649000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Colonic metastasis from mixed breast carcinoma masquerading as abemaciclib-associated diarrhea"],"prefix":"10.3389","volume":"16","author":[{"given":"Lin","family":"Lv","sequence":"first","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine","place":["Jinhua, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine","place":["Jinhua, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotao","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine","place":["Jinhua, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01384-6","article-title":"Invasive lobular carcinoma of the breast: the increasing importance of this special subtype","volume":"23","author":"McCart Reed","year":"2021","journal-title":"Breast Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70061","article-title":"Lobular breast cancer statistics, 2025","volume":"131","author":"Giaquinto","year":"2025","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15182356","article-title":"Invasive lobular carcinoma metastasis to the female genital tract: a systematic search and review of case reports and case series","volume":"15","author":"Koufopoulos","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1186\/bcr767","article-title":"Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome","volume":"6","author":"Arpino","year":"2004","journal-title":"Breast Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.65852","article-title":"Gastrointestinal metastases from lobular breast carcinoma: a literature review","volume":"16","author":"Kioleoglou","year":"2024","journal-title":"Cureus"},{"key":"B6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","article-title":"The CDK4\/6 inhibitor revolution - a game-changing era for breast cancer treatment","volume":"21","author":"Morrison","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4103\/0019-509x.134610","article-title":"Correlation of clinico-pathologic and radiologic parameters of response to neoadjuvant chemotherapy in breast cancer","volume":"51","author":"Mukherjee","year":"2014","journal-title":"Indian J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13531","article-title":"Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3","volume":"26","author":"Rugo","year":"2021","journal-title":"Oncologist"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2016.05.002","article-title":"Lobular breast cancer: clinical, molecular and morphological characteristics","volume":"212","author":"Christgen","year":"2016","journal-title":"Pathol Res Pract"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1186\/s12885-025-14404-5","article-title":"Efficacy and safety of small-molecule TKIs in neoadjuvant treatment of HER2-positive breast cancer: a systematic review and network meta-analysis","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nature13600","article-title":"Clonal evolution in breast cancer revealed by single nucleus genome sequencing","volume":"512","author":"Wang","year":"2014","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/s13244-025-02084-5","article-title":"Image-guided biopsy of breast lesions-when to use what biopsy technique","volume":"16","author":"Sanderink","year":"2025","journal-title":"Insights Imaging"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nature13556","article-title":"Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity","volume":"514","author":"Marusyk","year":"2014","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx273","article-title":"Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis","volume":"110","author":"Schrijver","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03981-4","article-title":"Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial","volume":"31","author":"Modi","year":"2025","journal-title":"Nat Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1802301\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:44:33Z","timestamp":1784090673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1802301\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":16,"alternative-id":["10.3389\/fonc.2026.1802301"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1802301","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"1802301"}}